التفاصيل البيبلوغرافية
| العنوان: |
(DXT67) Cognitive Functions over the Course of 5 Years in Multiple Sclerosis Patients Treated with Disease-Modifying Therapies. |
| المؤلفون: |
Ozakbas, Serkan, Baba, Cavid, Aslan, Taha, Sagici, Ozge, Simsek, Yasemin, Yigit, Pinar |
| المصدر: |
International Journal of MS Care; 2020, Vol. 22 Issue S2, p40-40, 1/4p |
| مصطلحات موضوعية: |
COGNITION, CONFERENCES & conventions, IMMUNOSUPPRESSIVE agents, MULTIPLE sclerosis, TIME |
| مستخلص: |
Background: Cognitive decline is common in multiple sclerosis (MS). Disease-modifying therapies (DMTs) are applied to delay or prevent disease progression in MS. While this has mostly been proven for physical status, comprehensive data on cognitive functions are not yet available. Objectives: We aimed to present 5 years of cognition data of patients treated with DMTs. Methods: In total, 756 patients with MS who were treated with interferon beta (1b or 1a, subcutaneous) (n = 342), glatiramer acetate (GA) (n = 188), or fingolimod (n = 226). Mean age was higher in the fingolimod group (P < .05). Physical disability was assessed with Expanded Disability Status Scale (EDSS), and cognitive status was assessed with Brief International Cognitive Assessment for MS (BICAMS) which included the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-II (CVLT-II), and the Brief Visuospatial Memory Test-Revised (BVMT-R). Assessments were performed at baseline and yearly until the end of fifth year of treatment. Results: 85% of patients treated with fingolimod were still having their medication at the end of fifth year (79% for GA and 78.9% for interferon beta, P < .05). Most of the patients treated with DMTs remained stable over the course of 5 years (fingolimod: 70.1%, interferons: 71.9%, GA: 75%, P > .05). Cognition improved in some patients (fingolimod: 11.2%, interferons: 9.6%, GA: 8%, P > .05). More than 80% of patients remained stable or improved. The most significant improvement was observed in SDMT, and it was significantly higher than CVLT-II and BVMT-R (30.7%, 18.6%, and 17%, respectively, P = .02). Conclusions: In conclusion, cognitive functions remain stable under DMTs over 5 years. This condition has not shown a relationship with the type of medication. Furthermore, SDMT seems to be the best predictor for cognitive change over time. [ABSTRACT FROM AUTHOR] |
|
Copyright of International Journal of MS Care is the property of Consortium of Multiple Sclerosis Centers and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
